These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 21367600)

  • 1. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
    Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
    Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Would general practitioners support a population-based colorectal cancer screening programme of faecal-occult blood testing?
    Tong S; Hughes K; Oldenburg B; Del Mar C
    Intern Med J; 2004; 34(9-10):532-8. PubMed ID: 15482265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
    Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
    Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Arsène D; Boutreux S; Tichet J; Launoy G
    Gut; 2007 Feb; 56(2):210-4. PubMed ID: 16891354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer test use--Maryland, 2002-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms.
    Dancourt V; Lejeune C; Lepage C; Gailliard MC; Meny B; Faivre J
    Eur J Cancer; 2008 Oct; 44(15):2254-8. PubMed ID: 18760592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2009 Feb; 29(4):450-7. PubMed ID: 19035980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of communicating social comparison information on risk perceptions for colorectal cancer.
    Lipkus IM; Klein WM
    J Health Commun; 2006 Jun; 11(4):391-407. PubMed ID: 16720537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attitudes, knowledge and practice of CRC screening among GPs in Queensland.
    Youl PH; Jackson C; Oldenburg B; Brown C; Dunn J; Aitken J
    Aust Fam Physician; 2006 Jul; 35(7):547-50. PubMed ID: 16820832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based estimate of the extent of colorectal cancer screening in Ontario.
    Rabeneck L; Paszat LF
    Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening colonoscopy and fecal occult blood testing practice patterns: a population-based survey of gastroenterologists.
    Rossi F; Sosa JA; Aslanian HR
    J Clin Gastroenterol; 2008; 42(10):1089-94. PubMed ID: 18936643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
    Clarke P; Jack F; Carey FA; Steele RJ
    Colorectal Dis; 2006 Jun; 8(5):389-92. PubMed ID: 16684082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.